{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:05Z","timestamp":1790820605296,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019522","name":"JCR Pharmaceuticals","doi-asserted-by":"publisher","award":["JCR Pharmaceuticals"],"award-info":[{"award-number":["JCR Pharmaceuticals"]}],"id":[{"id":"10.13039\/100019522","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with mucopolysaccharidosis type II (MPS II) can present with a severe neuronopathic phenotype or an attenuated non-neuronopathic phenotype. In the light of the recent development of drugs that cross the blood-brain barrier for treatment of neurologic MPS II symptoms, it is critical to define biomarkers that objectively differentiate phenotypes and monitor therapeutic outcomes of advanced treatments. In December 2023, a panel of Brazilian experts discussed the potential of quantifying heparan sulfate (HS) in the cerebrospinal fluid (CSF) as a biomarker for assessing neurological impairment in patients with MPS II, as well as the potential of the molecule as an objective parameter for therapeutic monitoring. Based on scientific evidence, the experts concluded that HS in CSF is predominantly derived from the brain and reflects neurological impairment in patients with MPS II. CSF HS levels may help differentiate between neuronopathic and non-neuronopathic forms of MPS II, with preliminary observations suggesting a potential threshold around 4,000 ng\/mL when HS quantification is performed using the same method described in clinical studies of pabinafusp alfa. According to the authors, monitoring HS levels in CSF can serve as an objective parameter for assessing the effectiveness of treatment with drugs that cross the blood-brain barrier. The recommended timing of HS evaluations in CSF of patients with the severe phenotype is: (i) before treatment; (ii) six months after starting treatment; and (iii) two years after starting treatment. The same monitoring scheme is recommended for patients with the attenuated MPS II phenotype, however, after two years of treatment, the physician may elect to perform regular neurocognitive evaluations instead of measuring HS in CSF. Lastly, the authors reinforced the importance of evaluating adherence to treatment, including interruptions, to provide a more meaningful assessment of the treatment\u2019s real-world impact and to determine the ideal timing of CSF collection for therapeutic monitoring.<\/jats:p>","DOI":"10.1186\/s13023-024-03463-9","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:44:52Z","timestamp":1732607092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis Type II: a position statement"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-3686","authenticated-orcid":false,"given":"Roberto","family":"Giugliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cec\u00edlia Menezes","family":"de Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson Santana","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Em\u00edlia Katiane E. A.","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson da Silva","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L\u00facia Schmitz Ferreira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmo","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"3463_CR1","first-page":"3421","volume-title":"Metab Mol Bases Inherit Dis","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly WS, editors. Metab Mol Bases Inherit Dis. New York: McGraw Hill; 2001. pp. 3421\u201352."},{"key":"3463_CR2","doi-asserted-by":"crossref","unstructured":"Fecarotta S, Tarallo A, Damiano C, Minopoli N, Parenti G. Pathogenesis of Mucopolysaccharidoses, an update. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21072515"},{"key":"3463_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2352-4642(17)30087-1","volume":"2","author":"R Giugliani","year":"2018","unstructured":"Giugliani R, Vairo F, Kubaski F, Poswar F, Riegel M, Baldo G, et al. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Lancet Child Adolesc Heal. 2018;2:56\u201368.","journal-title":"Lancet Child Adolesc Heal"},{"key":"3463_CR4","doi-asserted-by":"publisher","first-page":"165539","DOI":"10.1016\/j.bbadis.2019.165539","volume":"1865","author":"V De Pasquale","year":"2019","unstructured":"De Pasquale V, Pavone LM. Heparan sulfate proteoglycans: the sweet side of development turns sour in mucopolysaccharidoses. Biochim Biophys Acta - Mol Basis Dis. 2019;1865:165539.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"3463_CR5","doi-asserted-by":"crossref","unstructured":"Bosch ME, Kielian T. Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci [Internet]. 2015 [cited 2024 Jan 8];9. https:\/\/pubmed.ncbi.nlm.nih.gov\/26578874\/","DOI":"10.3389\/fnins.2015.00417"},{"key":"3463_CR6","doi-asserted-by":"crossref","unstructured":"Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab [Internet]. 2017 [cited 2024 Jan 8];37:3300\u201317. https:\/\/pubmed.ncbi.nlm.nih.gov\/28753105\/","DOI":"10.1177\/0271678X17722436"},{"key":"3463_CR7","doi-asserted-by":"crossref","unstructured":"Viana GM, Priestman DA, Platt FM, Khan S, Tomatsu S, Pshezhetsky AV. Brain Pathology in Mucopolysaccharidoses (MPS) patients with neurological forms. J Clin Med. 2020.","DOI":"10.3390\/jcm9020396"},{"key":"3463_CR8","doi-asserted-by":"crossref","unstructured":"Bigger BW, Begley DJ, Virgintino D, Pshezhetsky AV. Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders. Mol Genet Metab. 2018.","DOI":"10.1016\/j.ymgme.2018.08.003"},{"key":"3463_CR9","doi-asserted-by":"crossref","unstructured":"Morimoto H, Kida S, Yoden E, Kinoshita M, Tanaka N, Yamamoto R et al. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol Ther [Internet]. 2021 [cited 2024 Jan 9];29:1853\u201361. http:\/\/www.cell.com\/article\/S1525001621000277\/fulltext","DOI":"10.1016\/j.ymthe.2021.01.027"},{"key":"3463_CR10","doi-asserted-by":"crossref","unstructured":"Tanaka N, Kida S, Kinoshita M, Morimoto H, Shibasaki T, Tachibana K et al. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS. Mol Genet Metab [Internet]. 2018 [cited 2024 Jan 9];125:53\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/30064964\/","DOI":"10.1016\/j.ymgme.2018.07.013"},{"key":"3463_CR11","doi-asserted-by":"crossref","unstructured":"Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H et al. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial. Mol Ther [Internet]. 2019 [cited 2024 Jan 9];27:456\u201364. http:\/\/www.cell.com\/article\/S1525001618305896\/fulltext","DOI":"10.1016\/j.ymthe.2018.12.005"},{"key":"3463_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","volume":"57","author":"H Zhang","year":"2011","unstructured":"Zhang H, Young SP, Auray-Blais C, Orchard PJ, Tolar J, Millington DS. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57:1005\u201312.","journal-title":"Clin Chem"},{"key":"3463_CR13","doi-asserted-by":"crossref","unstructured":"Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M et al. A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther [Internet]. 2021 [cited 2024 Jan 9];29:671\u20139. http:\/\/www.cell.com\/article\/S1525001620304962\/fulltext","DOI":"10.1016\/j.ymthe.2020.09.039"},{"key":"3463_CR14","doi-asserted-by":"publisher","unstructured":"Constantopoulos G, Dekaban AS. Acid mucopolysaccharides in the cerebrospinal fluid of patients with Hunter\u2013Hurler\u2019s syndrome. J Neurochem [Internet]. 1970 [cited 2024 Jan 8];17:117\u201320. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/j.1471-4159.1970.tb00508.x","DOI":"10.1111\/j.1471-4159.1970.tb00508.x"},{"key":"3463_CR15","doi-asserted-by":"crossref","unstructured":"Giugliani R, Martins AM, So S, Yamamoto T, Yamaoka M, Ikeda T et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther [Internet]. 2021 [cited 2024 Jan 10];29:2378\u201386. http:\/\/www.cell.com\/article\/S1525001621001489\/fulltext","DOI":"10.1016\/j.ymthe.2021.03.019"},{"key":"3463_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0165-5728(01)00256-9","volume":"115","author":"W Pan","year":"2001","unstructured":"Pan W, Kastin AJ. Changing the chemokine gradient: CINC1 crosses the blood-brain barrier. J Neuroimmunol. 2001;115:64\u201370.","journal-title":"J Neuroimmunol"},{"key":"3463_CR17","doi-asserted-by":"crossref","unstructured":"Wang J, Bhalla A, Ullman JC, Fang M, Ravi R, Arguello A et al. High-throughput liquid chromatography\u2013Tandem Mass Spectrometry quantification of glycosaminoglycans as biomarkers of mucopolysaccharidosis II. Int J Mol Sci. 2020.","DOI":"10.3390\/ijms21155449"},{"key":"3463_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2022.07.017","volume":"137","author":"J Muenzer","year":"2022","unstructured":"Muenzer J, Burton BK, Harmatz P, Guti\u00e9rrez-Solana LG, Ruiz-Garcia M, Jones SA, et al. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2\/3 randomized study. Mol Genet Metab. 2022;137:127\u201339.","journal-title":"Mol Genet Metab"},{"key":"3463_CR19","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.ymgme.2023.107709","volume":"140","author":"J-H Seo","year":"2023","unstructured":"Seo J-H, Kosuga M, Hamazaki T, Shintaku H, Okuyama T. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: final report of 5-year results from a Japanese open-label phase 1\/2 study. Mol Genet Metab. 2023;140:107709.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03463-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:13:00Z","timestamp":1732608780000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03463-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3463"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03463-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RG declares research funding and\/or speaker honoraria and\/or consulting fees, received from Allievex, Amicus, Astellas, Avrobio, Azafaros, BioMarin, Chiesi, JCR, Novartis, Paradigm, Passage Bio, PTC, Regenxbio, Sanofi, Takeda, and Ultragenyx. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}